Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (<65 years) and older (≥65 years) patients in the CRUCIAL trial

References

• Arnold AM, Psaty BM, Kuller LH, et al. Incidence of cardiovascular disease in older Americans: the cardiovascular health study. J Am Geriatr Soc 2005;53:211-18
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220
   PubMed Web of Science ®Google Scholar
• Strategic Priorities. WHO. Available at: www.who.int/cardiovascular_diseases/priorities/en [Last accessed 23 May 2012]
   Google Scholar
• Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther 2007;21:297-309
   PubMed Web of Science ®Google Scholar
• Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Bähler C, Gutzwiller F, Erne P, et al. Lower age at first myocardial infarction in female compared to male smokers. Eur J Prev Cardiol 2011;19:1184-93
   PubMed Web of Science ®Google Scholar
• Ulmer H, Kelleher C, Diem G, et al. Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system: The Vorarlberg Health Monitoring & Promotion Programme. Eur Heart J 2003;24:1004-13
   PubMed Web of Science ®Google Scholar
• General Lifestyle Overview: A report on the 2010 General Lifestyle Survey. Office for National Statistics. Available at: www.ons.gov.uk [Last accessed 2 October 2012]
   Google Scholar
• Jackson R, Chambless L, Higgins M, et al. Sex difference in ischaemic heart disease mortality and risk factors in 46 communities: an ecologic analysis. Cardiovasc Risk Factors 1997;7:43-54
   Google Scholar
• McDonald M, Hertz RP, Unger AN, et al. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009;64:256-63
   PubMed Web of Science ®Google Scholar
• Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006;98:204-8
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3
   PubMed Web of Science ®Google Scholar
• Collier DJ, Poulter NR, Dahlöf B, et al. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens 2011;29:583-91
   PubMed Web of Science ®Google Scholar
• Collier DJ, Poulter NR, Dahlöf B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA). J Hypertens 2011;29:592-9
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Doonan RJ, Mikhailidis DP. Undertreatment of hypercholesterolemia. Curr Med Res Opin 2010;26:439-43
   PubMed Web of Science ®Google Scholar
• Zamorano J, Erdine S, Lopez AP, et al. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010;122:7-15
   PubMed Web of Science ®Google Scholar
• Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011;27:821-33
   PubMed Web of Science ®Google Scholar
• Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005;7:264-73
   PubMedGoogle Scholar
• Erdine S, Ro YM, Tse HF, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009;23:196-210
   PubMed Web of Science ®Google Scholar
• Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 2008;83:35-45
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Gensini G, Mancini GB, et al. An international open-label program to assess the efficacy of single-pill amlodipine/atorvastatin in attaining recommended BP and lipid levels: The JEWEL Programme. Eur J Cardiovasc Prev Rehabil 2009;16:472-80
   PubMed Web of Science ®Google Scholar
• Feldman R, Flack J, Howes L, et al. Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis. Curr Med Res Opin 2012;28:1421-33
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord 2010;10:29
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
   PubMed Web of Science ®Google Scholar
• Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006–2010. Med J Aust 2011;195:134-7
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus ≥65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study. Am J Cardiol 2009;103:577-82
   PubMed Web of Science ®Google Scholar
• Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007;5:52-63
   PubMedGoogle Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm [Last accessed 12 March 2013]
   Google Scholar
• Hey-Hadavi JH, Kuntze E, Luo D, et al. Tolerability of atorvastatin in a population aged ≥65 years: A retrospective pooled analysis of results from fifty randomized clinical trials. Am J Geriatr Pharmacother 2006;4:112-22
   PubMedGoogle Scholar
• Medical Research Council. MRC Cluster Randomized Trials: Methodological and Ethical Considerations. London: MRC, 2002
   Google Scholar